Cisplatin and etoposide versus cyclophosphamide, epirubicin and vincristine in small cell lung cancer: a randomised study
| Autor: | G. Cartel, O. Nascimben, S. Foladore, S. Monfardini, M.Delia Valentina, M. D. Magri, D. CriveUari, A. Sibau, Marco Trovo, Andrea Veronesi, R. Talamini |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Vincristine Lung Neoplasms Cyclophosphamide medicine.medical_treatment Gastroenterology Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Carcinoma Small Cell Etoposide Aged Epirubicin Chemotherapy Performance status business.industry Respiratory disease Middle Aged medicine.disease Surgery Radiation therapy Oncology Female Cisplatin business medicine.drug |
| Zdroj: | European Journal of Cancer. 30:1474-1478 |
| ISSN: | 0959-8049 |
| DOI: | 10.1016/0959-8049(94)00253-2 |
| Popis: | From September 1986 until December 1991, 139 patients with histologically-proven small cell lung cancer, age 40, absence of brain metastases and no previous treatment, were randomised to receive either CEV cyclophosphamide 1000 mg/m2 intravenous (i.v.), epirubicin 70 mg/m2 i.v., vincristine 1.2 mg/m2 i.v., every 3 weeks or PE (cisplatin 20 mg/m2 i.v. and etoposide 75 mg/m2 i.v. for 5 consecutive days, every 3 weeks) for six cycles. After three cycles, responding patients received radiotherapy to the chest (45 Gy/15 sessions) and to the brain (30 Gy/10 sessions—only in patients with limited disease achieving complete remission). 3 patients were ineligible. Patient characteristics included (CEV/PE) total number 66 70 , median age 60 61 years , median performance status 80 80 , extended disease 33 48 cases (P = 0.04). In evaluable patients, 42 62 (67.7%) responded to CEV while 42 58 (72.4%) responded to PE (P = non-significant); respective complete response rates were 16.1 and 29.3% (P = non-significant) and respective complete response rates in patients with extended disease were 9.4 and 28.9% (P = 0.03). Median survival was 10.5 months, without significant differences in the two treatment arms, even after adjustment for stage. PE was less well tolerated than CEV. Although PE is more active than CEV in certain subsets of patients, its apparent inability to improve survival in this and in other studies questions its routine use in small cell lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|